The Technical Analyst
Karyopharm Therapeutics [KPTI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Karyopharm Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-4.35% $1.100
America/New_York / 7 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 128.11 mill |
| EPS: | -1.250 |
| P/E: | -0.880 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 116.47 mill |
| Avg Daily Volume: | 1.379 mill |
| RATING 2024-05-07 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.880 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -0.880 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.952 - 1.248 ( +/- 13.45%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-06 | Paulson Richard A. | Sell | 3 576 | Common Stock |
| 2024-04-22 | Rangwala Reshma | Sell | 6 789 | Common Stock |
| 2024-04-04 | Paulson Richard A. | Sell | 3 563 | Common Stock |
| 2024-03-05 | Paulson Richard A. | Sell | 3 573 | Common Stock |
| 2024-02-29 | Rangwala Reshma | Sell | 15 667 | Common |
| INSIDER POWER |
|---|
| 69.71 |
| Last 99 transactions |
| Buy: 2 857 011 | Sell: 550 783 |
Forecast:
16:00 - $1.110
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.110
Forecast 2: 16:00 - $1.110
Forecast 3: 16:00 - $1.110
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.100 (-4.35% ) |
| Volume | 0.986 mill |
| Avg. Vol. | 1.379 mill |
| % of Avg. Vol | 71.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KPTI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.490 | N/A | Active |
|---|
KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Latest Press Releases
2024-05-02 16:30:00 - Press Release
Karyopharm To Report First Quarter 2024 Financial Results On May 8, 2024
-- conference call scheduled for wednesday, may 8, 2024, at 8:00 a.m. et -- newton, mass.
2024-05-01 16:05:00 - Press Release
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Newton, mass. , may 1, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the company granted an aggregate of 72,700 restricted stock units (rsus) to five newly-hired employees.
2024-04-24 16:01:00 - Press Release
Karyopharm Announces Presentations In Endometrial Cancer And Myelofibrosis At The 2024 American Society Of Clinical Oncology Annual Meeting
Invited to present updated endometrial cancer data during special session "asco plenary series: rapid abstract updates" newton, mass. , april 24, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 american society of clinical oncology annual meeting (2024 asco annual meeting) being held may 31 - june 4 in chicago, il.
2024-04-01 16:05:00 - Press Release
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Newton, mass. , april 1, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the company granted an aggregate of 79,800 restricted stock units (rsus) to five newly-hired employees.
2024-03-06 16:05:00 - Press Release
Karyopharm To Participate At Barclays 26th Annual Global Healthcare And Leerink Partners Global Biopharma Conferences
Newton, mass. , march 6, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the company's senior management team will participate in the leerink partners global biopharma conference on tuesday, march 12, 2024 and present at the barclays 26th annual global healthcare conference in a fireside chat on wednesday, march 13, 2024 at 9:00 a.m.
Latest News
2024-05-02 16:30:00 - PRNewsWire
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
-- Conference Call Scheduled for Wednesday, May 8, 2024, at 8:00 a.m. ET -- NEWTON, Mass.
2024-04-30 14:28:23 - Seeking Alpha
Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts
Karyopharm Therapeutics Inc.'s selinexor is being featured in 7 presentations at ASCO. The company is also exploring selinexor's potential role in myelofibrosis, with two key trials planned. Karyopharm Therapeutics' cash position is a challenge, but success in any of their pivotal trials could be a game changer for selinexor's prospects.
2024-02-29 09:41:07 - Zacks Investment Research
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.43 per share a year ago.
2024-02-25 13:37:41 - InvestorPlace
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
2024-02-14 11:06:16 - Zacks Investment Research
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-11-02 14:25:25 - Seeking Alpha
Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - CFO Conference Call Participants Maury Raycroft - Jefferies Colleen Kusy - Baird Operator Good morning. My name is Guru and I will be your conference operator today.
2023-08-03 10:48:49 - PennyStocks
Penny Stocks To Buy Now? 3 With Ratings Up To 1,742%
In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts.
2023-08-02 10:28:01 - Zacks Investment Research
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.62 per share a year ago.
2023-07-18 08:09:50 - InvestorPlace
Why Is Karyopharm Therapeutics (KPTI) Stock Up 21% Today?
Karyopharm Therapeutics (NASDAQ: KPTI ) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. The Food and Drug Administration (FDA) has granted fast-track designation to the development of selinexor.
2023-07-05 13:02:10 - Zacks Investment Research
All You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to Buy
Karyopharm Therapeutics (KPTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).